Your browser doesn't support javascript.
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.
Gonçalves, Antonio; Bertrand, Julie; Ke, Ruian; Comets, Emmanuelle; de Lamballerie, Xavier; Malvy, Denis; Pizzorno, Andrés; Terrier, Olivier; Rosa Calatrava, Manuel; Mentré, France; Smith, Patrick; Perelson, Alan S; Guedj, Jérémie.
  • Gonçalves A; Université de Paris, IAME, INSERM, Paris, France.
  • Bertrand J; Université de Paris, IAME, INSERM, Paris, France.
  • Ke R; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
  • Comets E; Université de Paris, IAME, INSERM, Paris, France.
  • de Lamballerie X; Institut Hospitalo-Universitaire Méditerranée Infection, UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Marseille, France.
  • Malvy D; Inserm, UMR 1219, Université de Bordeaux, Bordeaux, France.
  • Pizzorno A; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Terrier O; CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • Rosa Calatrava M; CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • Mentré F; CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • Smith P; Université de Paris, IAME, INSERM, Paris, France.
  • Perelson AS; Certara, Integrated Drug Development, Princeton, New Jersey, USA.
  • Guedj J; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
CPT Pharmacometrics Syst Pharmacol ; 9(9): 509-514, 2020 09.
Article in English | MEDLINE | ID: covidwho-603799
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome-coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6-87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: CPT Pharmacometrics Syst Pharmacol Year: 2020 Document Type: Article Affiliation country: Psp4.12543

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: CPT Pharmacometrics Syst Pharmacol Year: 2020 Document Type: Article Affiliation country: Psp4.12543